行情

ASND

ASND

Ascendis制药
NASDAQ

实时行情|Nasdaq Last Sale

103.36
-1.62
-1.54%
已收盘, 16:00 09/17 EDT
开盘
104.09
昨收
104.98
最高
106.40
最低
103.18
成交量
14.81万
成交额
--
52周最高
133.96
52周最低
53.21
市值
49.14亿
市盈率(TTM)
-22.5820
分时
5日
1月
3月
1年
5年

分析师评级

10位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ASND 新闻

  • 日本社交巨头Line推出加密交易平台Bitmax
  • TechWeb.39分钟前
  • WeWork拟今年完成IPO:估值缩水八成,创始人表悔意
  • 澎湃新闻.45分钟前
  • 财经天下:IMF新掌门将面临哪些挑战?
  • 中国新闻网.49分钟前
  • 13家大型投行前瞻:美联储料降息25个基点 微调声明
  • 汇通网.53分钟前

更多

所属板块

生物技术和医学研究
+0.26%
制药与医学研究
+0.57%

热门股票

名称
价格
涨跌幅

ASND 简况

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications. In addition to TransCon hGH, the Company has developed a pipeline of long-acting prodrug product candidates, such as TransCon Treprostinil for the treatment of pulmonary arterial hypertension (PAH), TransCon Peptides for the treatment of diabetes and TransCon Ranibizumab for the treatment of ophthalmology. It is also using its TransCon technology platform to develop TransCon Parathyroid Hormone (TransCon PTH) for hypoparathyroidism, a rare endocrine disorder of calcium and phosphate metabolism.
展开

Webull提供Ascendis Pharma A/S的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。